Market Place
Sourcing Support
Merrimack Dissolution, $15.10 Liquidating Dividend Approved
10 May 2024 //
BUSINESSWIRE
Merrimack Anticipated Liquidation Distribution Amount
09 May 2024 //
BUSINESSWIRE
Merrimack to Voluntarily Delist, Subject to Dissolution Approval
30 Apr 2024 //
BUSINESSWIRE
Merrimack Receives $225 Million Milestone Payment from Ipsen
27 Mar 2024 //
BUSINESSWIRE
Merrimack Reports Full Year 2023 Financial Results
07 Mar 2024 //
BUSINESSWIRE
Merrimack Reports Third Quarter 2023 Financial Results
02 Nov 2023 //
BUSINESSWIRE
Merrimack Reports Second Quarter 2023 Financial Results
03 Aug 2023 //
BUSINESSWIRE
Merrimack Reports Full Year 2022 Financial Results
09 Mar 2023 //
BUSINESSWIRE
Merrimack Provides Ipsen Report That Onivyde® Regimental Adenocarcinoma
09 Nov 2022 //
BUSINESSWIRE
Merrimack Reports Second Quarter 2022 Financial Results
04 Aug 2022 //
BUSINESSWIRE
Merrimack Reports First Quarter 2022 Financial Results
05 May 2022 //
BUSINESSWIRE
Merrimack Reports Full Year 2021 Financial Results
09 Mar 2022 //
BUSINESSWIRE
Statement of changes in beneficial ownership of securities
22 Feb 2022 //
PRESS RELEASE
Merrimack Pharmaceuticals (NASDAQ:MACK) Coverage Initiated at StockNews.com
22 Feb 2022 //
MARKETBEAT
Statement of changes in beneficial ownership of securities
18 Feb 2022 //
PRESS RELEASE
Merrimack Pharmaceuticals (NASDAQ:MACK) Coverage Initiated at StockNews.com
04 Feb 2022 //
MARKETBEAT
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.